% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{Lohmann:865149,
      author       = {Lohmann, Philipp and Stavrinou, P. and Lipke, K. and Bauer,
                      E. K. and Ceccon, G. and Werner, J. and Fink, G. R. and
                      Shah, N. J. and Langen, K. J. and Galldiks, N.},
      title        = {{S}patial discrepancies between {FET} {PET} and
                      conventional {MRI} in patients with newly diagnosed
                      glioblastoma},
      reportid     = {FZJ-2019-04699},
      year         = {2019},
      abstract     = {P14.32 SPATIAL DISCREPANCIES BETWEEN FET PET AND
                      CONVENTIONAL MRI IN PATIENTS WITH NEWLY DIAGNOSED
                      GLIOBLASTOMAP. Lohmann1, P. Stavrinou2, K. Lipke1, E. K.
                      Bauer3, G. Ceccon3, J. Werner3, G. R. Fink1,3, N. J.
                      Shah1,4, K. Langen1,5, N. Galldiks1,3; 1Institute of
                      Neuroscience and Medicine (INM-3,-4), Research Center
                      Juelich, Juelich, Germany, 2Department of Neurosurgery,
                      Faculty of Medicine and University Hospital Cologne,
                      University of Cologne, Cologne, Germany, 3Department of
                      Neurology, Faculty of Medicine and University Hospital
                      Cologne, University of Cologne, Cologne, Germany,
                      4Department of Neurology, University Hospital RWTH Aachen,
                      Aachen, Germany, 5Department of Nuclear Medicine, University
                      Hospital RWTH Aachen, Aachen, Germany.BACKGROUND: In
                      patients with glioblastoma, the tissue showing contrast
                      enhancement (CE) in MRI is usually the target for resection
                      or radiotherapy. However, the solid tumor mass typically
                      extends beyond the area of CE. Amino acid PET can detect
                      tumor parts that show no CE. We systematically investigated
                      tumor volumes delineated by amino acid PET and MRI in newly
                      diagnosed, untreated glioblastoma patients. MATERIAL AND
                      METHODS: Preoperatively, 50 patients with subse-quently
                      neuropathologically confirmed glioblastoma underwent
                      O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET,
                      fluid-attenuated inversion recovery (FLAIR), and CE MRI.
                      Areas of CE were manually delineated. FET PET tumor volumes
                      were segmented using a tumor-to-brain ratio ≥ 1.6. The
                      per-centage of overlapping volumes (OV), as well as Dice and
                      Jaccard spatial similarity coefficients (DSC; JSC), were
                      calculated. FLAIR images were evalu-ated visually. RESULTS:
                      In $86\%$ of patients (n = 43), the FET PET tumor volume was
                      significantly larger than the volume of CE (21.5 ± 14.3 mL
                      vs. 9.4 ± 11.3 mL; P < 0.001). Forty patients $(80\%)$
                      showed both an increased uptake of FET and CE. In these 40
                      patients, the spatial similarity between FET and CE was low
                      (mean DSC, 0.39 ± 0.21; mean JSC, 0.26 ± 0.16). Ten
                      patients $(20\%)$ showed no CE, and one of these patients
                      showed no FET uptake. In $10\%$ of patients (n = 5),
                      increased FET uptake was present out-side of areas of FLAIR
                      hyperintensity. CONCLUSION: Our results show that the
                      metabolically active tumor volume delineated by FET PET is
                      signifi-cantly larger than tumor volume delineated by CE.
                      The data strongly suggest that the information derived from
                      FET PET should be integrated into the management of newly
                      diagnosed glioblastoma patients. FUNDING: This work was
                      supported by the Wilhelm-Sander Stiftung, Germany},
      month         = {Sep},
      date          = {2019-09-19},
      organization  = {14th Meeting of the European
                       Association of Neurooncology, Lyon
                       (Frankreich), 19 Sep 2019 - 22 Sep
                       2019},
      subtyp        = {Invited},
      cin          = {INM-3 / INM-4},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)6},
      url          = {https://juser.fz-juelich.de/record/865149},
}